EN
Patient-first cell therapy innovation
 
Technology
  • TRUST Platform
    TRUST Platform
    Our Unique Drug Discovery Platform. High-throughput discovery platform that identifies TCR in 6 weeks as compared to years of industry average.
    Our Unique Drug Discovery Platform. High-throughput discovery platform that identifies TCR in 6 weeks as compared to years of industry average.
  • CHECK-T Armored T-Cell Platform
    CHECK-T Armored T-Cell Platform
    CHECK-T Armored T-Cell Platform to Combat Immunosuppression. Next generation Cell drug armored with checkpoint blockade to improve solid tumor outcomes.
    CHECK-T Armored T-Cell Platform to Combat Immunosuppression. Next generation Cell drug armored with checkpoint blockade to improve solid tumor outcomes.
  • TURBO-T Platform
    TURBO-T Platform
    TURBO-T Platform for Tumor Cell Heterogeneity. New generation TCRT armored with tumor microenvironment reconditioning agent to enable the endogenous immunity against tumor heterogeneity.
    TURBO-T Platform for Tumor Cell Heterogeneity. New generation TCRT armored with tumor microenvironment reconditioning agent to enable the endogenous immunity against tumor heterogeneity.
  • GMP-grade and industry-scale vector production and cell manufacturing platform
    GMP-grade and industry-scale vector production and cell manufacturing platform
    Industrialized production of GMP-grade vectors and engineered immune cells are the basis for clinical development of immune cell therapy. The Chongqing site was launched in 2017, and the facilities in LA and Guangzhou were launched in 2019 and 2020, respectively.
    Industrialized production of GMP-grade vectors and engineered immune cells are the basis for clinical development of immune cell therapy. The Chongqing site was launched in 2017, and the facilities in LA and Guangzhou were launched in 2019 and 2020, respectively.
  • NK Cell Platform
    NK Cell Platform
    Optimize cord blood NK cell isolation, culturing, transgene, proliferation and differentiation technologies to ensure efficient transfection and amplification of NK cells. The unique drug design gives full play to the advantages of NK cells as general drugs and spot drugs.
    Optimize cord blood NK cell isolation, culturing, transgene, proliferation and differentiation technologies to ensure efficient transfection and amplification of NK cells. The unique drug design gives full play to the advantages of NK cells as general drugs and spot drugs.
  • Clinical immune monitoring
    Clinical immune monitoring
    TCRCure’s deep sequencing and big data analysis platform supports immune monitoring services. This service can provide valuable data to pharmaceutical companies running clinical trials on immunotherapy drugs. TCRCure has already provided this service to many well-known pharmaceutical companies including BMS.
    TCRCure’s deep sequencing and big data analysis platform supports immune monitoring services. This service can provide valuable data to pharmaceutical companies running clinical trials on immunotherapy drugs. TCRCure has already provided this service to many well-known pharmaceutical companies including BMS.


Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
About TCRCure
Research and Development
Products and Clinic
News and Media
Recruitment

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer